MediWound to Present at Upcoming Investor Conferences
MediWound Ltd. (Nasdaq: MDWD), a biopharmaceutical company specializing in advanced therapeutic solutions for tissue repair, announced presentations at key investor conferences in September 2021. The company will participate in the 2021 Wells Fargo Virtual Healthcare Conference on September 9 at 8:00 a.m. ET and the H.C. Wainwright 23rd Annual Global Investment Conference with an on-demand presentation available starting September 13. The company focuses on innovative products like NexoBrid and EscharEx for burn care and wound management.
- None.
- None.
YAVNE, Israel, Sept. 03, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management will present at the following investor conferences during the month of September 2021.
2021 Wells Fargo Virtual Healthcare Conference
Date: Thursday, September 9, 2021
Presentation Time: 8:00 a.m. Eastern Time
H.C. Wainwright 23rd Annual Global Investment Conference
On-demand corporate presentation is available beginning at 7:00 AM ET on Monday, September 13, 2021
A live webcast of each event will be available on the Events page of the Investors section of the Company's website: www.mediwound.com. A replay of each webcast will be available on the Company’s website for approximately 30 days.
About MediWound Ltd.
MediWound is a biopharmaceutical company that develops, manufactures, and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Our strategy leverages our enzymatic technology platform, focused on next-generation bioactive therapies for burn care, wound care and tissue repair.
NexoBrid, our commercial orphan biological product for non-surgical eschar removal of deep-partial and full-thickness thermal burns, is a bromelain-based biological product containing a sterile mixture of proteolytic enzymes that selectively removes burn eschar within four hours without harming surrounding viable tissue. NexoBrid is currently marketed in the European Union and other international markets and is at registration-stage in the U.S. NexoBrid is supported by the U.S. Biomedical Advanced Research and Development Authority (BARDA).
EscharEx, our next-generation bioactive topical therapeutic under development in the U.S. for debridement of chronic and hard to heal wounds. In two Phase 2 studies, EscharEx was well-tolerated and has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, within a few daily applications.
MW005, our topical biological drug for the treatment of non-melanoma skin cancers, is a clinical-stage product candidate under development.
Committed to innovation, we are dedicated to improving quality of care and patient lives. For more information, please visit www.mediwound.com.
| Contacts: | Jeremy Feffer |
| Boaz Gur-Lavie | Managing Director |
| Chief Financial Officer | LifeSci Advisors |
| MediWound Ltd. | 212-915-2568 |
| ir@mediwound.com | jeremy@lifesciadvisors.com |
FAQ
What is the date of MediWound's presentation at the Wells Fargo Virtual Healthcare Conference?
When will the H.C. Wainwright conference presentation be available for MediWound?
What are MediWound's main products mentioned in the press release?
Where is NexoBrid marketed?
What technology does MediWound utilize in its products?
